AI assistant
CANN GROUP LIMITED — Share Issue/Capital Change 2023
Dec 14, 2023
64603_rns_2023-12-14_8a8dd3e3-d95f-4bb0-ae09-15b928d57585.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Not for distribution or release in the United States
==> picture [114 x 53] intentionally omitted <==
ASX ANNOUNCEMENT
15 December 2023 Expiry of escrow restrictions
15 December 2023 – Cann Group Limited (ASX: CAN) ( Cann or the Company ) advises that, in accordance with Listing Rule 3.10A, 2,662,398 fully paid ordinary shares, which are currently classified as voluntarily restricted securities, will cease to be escrowed from 22 December 2023.
Authorised for release by the Board of Directors, Cann Group Limited.
For all media enquiries please contact:
Jackson Paine Corporate Communications Manager +61 439 492 955 [email protected]
For all other information please contact:
Peter Koetsier Steven Notaro CEO Head of Legal & Regulatory Affairs & Cann Group Limited Company Secretary +61 3 9095 7088 Cann Group Limited [email protected] +61 3 9095 7088 [email protected]
About Cann Group
Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology. Learn more at: www.canngrouplimited.com | www.satipharm.com
Cann Group Limited
ACN 25 603 949 739, Australia 262-276 Lorimer Street, Port Melbourne 3207, Victoria, Australia Tel +61 (0) 3 9095 7088 | www.canngrouplimited.com